SG11201401065RA - Dosage regimen for an s1p receptor modulator or agonist - Google Patents

Dosage regimen for an s1p receptor modulator or agonist

Info

Publication number
SG11201401065RA
SG11201401065RA SG11201401065RA SG11201401065RA SG11201401065RA SG 11201401065R A SG11201401065R A SG 11201401065RA SG 11201401065R A SG11201401065R A SG 11201401065RA SG 11201401065R A SG11201401065R A SG 11201401065RA SG 11201401065R A SG11201401065R A SG 11201401065RA
Authority
SG
Singapore
Prior art keywords
agonist
dosage regimen
receptor modulator
modulator
receptor
Prior art date
Application number
SG11201401065RA
Other languages
English (en)
Inventor
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201401065R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201401065RA publication Critical patent/SG11201401065RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201401065RA 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist SG11201401065RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549847P 2011-10-21 2011-10-21
PCT/EP2012/070692 WO2013057212A1 (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Publications (1)

Publication Number Publication Date
SG11201401065RA true SG11201401065RA (en) 2014-09-26

Family

ID=47022722

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201401065RA SG11201401065RA (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist
SG10201602279PA SG10201602279PA (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201602279PA SG10201602279PA (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Country Status (17)

Country Link
US (1) US20150218090A1 (zh)
EP (1) EP2768494A1 (zh)
JP (1) JP2014530835A (zh)
KR (1) KR20140084041A (zh)
CN (1) CN103889408A (zh)
AU (1) AU2012324867B2 (zh)
BR (1) BR112014009141A8 (zh)
CA (1) CA2852142A1 (zh)
CL (1) CL2014000991A1 (zh)
IL (1) IL231945A0 (zh)
MX (1) MX2014004813A (zh)
RU (1) RU2014120411A (zh)
SG (2) SG11201401065RA (zh)
TN (1) TN2014000132A1 (zh)
TW (1) TW201320998A (zh)
WO (1) WO2013057212A1 (zh)
ZA (1) ZA201402283B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
EP3168237A1 (en) * 2015-11-10 2017-05-17 Dow Global Technologies LLC High pressure, free radical polymerizations to produce ethylene-based polymers
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
US20230295076A1 (en) * 2020-08-20 2023-09-21 Medshine Discovery Inc. Acetophenone oxime compound and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
CA2524054C (en) * 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2006058316A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PT2952177T (pt) * 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
JO3044B1 (ar) * 2008-12-22 2016-09-05 Novartis Ag نظام تناول جرعة لمنبه مستقبل s1p
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
WO2013057212A1 (en) 2013-04-25
BR112014009141A8 (pt) 2017-06-20
TW201320998A (zh) 2013-06-01
BR112014009141A2 (pt) 2017-06-13
RU2014120411A (ru) 2015-11-27
CA2852142A1 (en) 2013-04-25
MX2014004813A (es) 2014-05-20
AU2012324867A1 (en) 2014-05-08
TN2014000132A1 (en) 2015-07-01
CL2014000991A1 (es) 2014-08-22
CN103889408A (zh) 2014-06-25
KR20140084041A (ko) 2014-07-04
AU2012324867B2 (en) 2015-09-10
NZ623571A (en) 2016-03-31
SG10201602279PA (en) 2016-04-28
EP2768494A1 (en) 2014-08-27
ZA201402283B (en) 2015-03-25
JP2014530835A (ja) 2014-11-20
US20150218090A1 (en) 2015-08-06
IL231945A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
HUS2000017I1 (hu) S1P receptor agonista adagolási rendje
ZA201103863B (en) Dosage regimen for s1p receptor agonist
ZA201404270B (en) Dosage regimen of an s1p receptor modulator
PT2794626T (pt) Compostos de antagonistas de e-selectina
IL231741A0 (en) A modulator device with a configuration for implantation
HK1201737A1 (zh) 藥物化合物
IL228422A0 (en) Hormone nuclear protein modulators
PL2527262T3 (pl) Urządzenie do napełniania pojemników
PL2527260T3 (pl) Urządzenie do napełniania pojemników
PL2748105T3 (pl) Urządzenie napełniające
EP2709621A4 (en) POSITIVE ALLOSERIC MODULATORS OF M1 RECEPTOR TO QUINOLINE-AMIDE N-BINDING
EP2725081A4 (en) RESIN FOR A SCINTILLATOR
ZA201402283B (en) Dosage regimen for an s1p receptor modulator or agonist
AP3669A (en) Method for metering hydrocarbons
EP2796459A4 (en) NEW S1P RECEIVER MODULATOR
PL2688388T3 (pl) Układ plandeki do zasobnika
HK1197015A1 (zh) 藥劑分包裝置
GB201114838D0 (en) Filling device for an anaesthetic dispenser
SI2357151T1 (sl) Naprava za porazdelitev medija za polnilna postrojenja
GB2487271B (en) Filling system
PL2527261T3 (pl) Urządzenie do napełniania pojemników
PL120345U1 (pl) Urzadzenie do wydawania wkladów
GB201114944D0 (en) Filling device
PL120160U1 (pl) Urzadzenie do granulacji - granulator
PT2567737T (pt) Dispositivo de compensação de um nível de enchimento